| Dr Michael Lawrence Shelling, MD | |
|
10075 S Jog Rd, Ste 206, Boynton Beach, FL 33437-3536 | |
| (561) 737-1100 | |
| (561) 731-4419 |
| Full Name | Dr Michael Lawrence Shelling |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 16 Years |
| Location | 10075 S Jog Rd, Boynton Beach, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598924896 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | ME111217 (Florida) | Primary |
| Entity Name | Michael L Shelling Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750646428 PECOS PAC ID: 3375790629 Enrollment ID: O20120822000167 |
News Archive
MRIGlobal today announced that it has been awarded a $14.8 million contract to develop an end-to-end next generation sequencing system for clinical diagnosis of infectious diseases.
Optimer Pharmaceuticals, Inc. today announced positive top-line results from the second of two pivotal Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI). This study was conducted in approximately 100 clinical sites throughout North America and Europe. The Company plans to use data from this study to support submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2010.
The risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat, meaning that a large portion of the population has an unrecognized risk of developing cancer.
A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's disease (PD).
Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer (CRC) with high microsatellite instability (MSI-H), a predisposition that occurs in 15% of all CRCs causing significantly different prognosis and response to treatment.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Lawrence Shelling, MD 10075 S Jog Rd, Ste 206, Boynton Beach, FL 33437-3536 Ph: (561) 737-1100 | Dr Michael Lawrence Shelling, MD 10075 S Jog Rd, Ste 206, Boynton Beach, FL 33437-3536 Ph: (561) 737-1100 |
News Archive
MRIGlobal today announced that it has been awarded a $14.8 million contract to develop an end-to-end next generation sequencing system for clinical diagnosis of infectious diseases.
Optimer Pharmaceuticals, Inc. today announced positive top-line results from the second of two pivotal Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI). This study was conducted in approximately 100 clinical sites throughout North America and Europe. The Company plans to use data from this study to support submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2010.
The risk of invasive breast cancer is increased in postmenopausal women with a normal body mass index (BMI) but higher levels of body fat, meaning that a large portion of the population has an unrecognized risk of developing cancer.
A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's disease (PD).
Caris Life Sciences, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the results of a study identifying the clinical benefit of targeted therapy in colorectal cancer (CRC) with high microsatellite instability (MSI-H), a predisposition that occurs in 15% of all CRCs causing significantly different prognosis and response to treatment.
› Verified 4 days ago
Dr. Julian Mackay-wiggan, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9897 Hagen Ranch Rd, Boynton Beach, FL 33472 Phone: 561-364-7774 Fax: 561-364-7775 | |
Dr. Robyn Dale Siperstein, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9897 Hagen Ranch Road, Boynton Beach, FL 33472 Phone: 561-364-7774 Fax: 561-364-7775 | |
Dr. Laju M Mathew, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9897 Hagen Ranch Rd, Boynton Beach, FL 33437 Phone: 561-364-7774 | |
Ellis J Gottesfeld, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 7730 Boynton Beach Blvd, #4, Boynton Beach, FL 33437 Phone: 561-572-0299 Fax: 561-572-2596 | |
Michael Ian Shiman, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 10075 S Jog Rd, Ste 306, Boynton Beach, FL 33437 Phone: 561-424-7546 Fax: 561-244-6133 | |
Dr. Frances S Rotter, MD Dermatology Medicare: Medicare Enrolled Practice Location: 715 W Boynton Beach Blvd Ste C, Boynton Beach, FL 33426 Phone: 561-737-8376 Fax: 561-509-7068 | |
Dr. Amelia G Damse, D.O., M.P.H. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 10151 Enterprise Ctr Ste 204, Boynton Beach, FL 33437 Phone: 561-405-3000 Fax: 561-459-1444 |